SNY

Sanofi ADS
D

SNY

Arincen75/100B

Sanofi ADS return on equity (ROE)

Sanofi ADS's return on equity is 5.43%: net income of 3.96B EUR over the last twelve months on shareholders' equity of 72.88B EUR.

Today
5.43%
Average, 5 years
13.38%
Low, 5 years
5.72%
High, 5 years
17.55%

ROE (return on equity) = net income (last 12 months) ÷ shareholders' equity = 3.96B ÷ 72.88B = 5.43%

ROE (return on equity)
Net income
Shareholders' equity

Each quarter's net income over its last four quarters, over the shareholders' equity at the quarter end.

What drives Sanofi ADS's return on equity?

Net margin
16.7%
profit on each dollar of sales
Asset turnover
0.37×
sales on each dollar of assets
Equity multiplier
1.78×
assets on each dollar of equity
Return on equity
10.9%
FY2025
  • FY202516.7% × 0.37 × 1.78 = 10.9%
  • FY202412.6% × 0.33 × 1.71 = 7.2%
  • FY202313.0% × 0.33 × 1.71 = 7.3%
  • FY202220.6% × 0.32 × 1.69 = 11.2%
  • FY202115.9% × 0.33 × 1.75 = 9.1%

The DuPont breakdown, on each year-end's assets and equity, as the return on equity elsewhere on this page. A high equity multiplier means a small equity base: debt, or buybacks that return the equity to shareholders, lift the return on what is left.

ROE (return on equity) by year and by quarter

Fiscal yearPeriod endingROE (return on equity)Net incomeShareholders' equity
Today5.43%3.96B72.88B
FY202531 Dec 20257.81%5.57B71.38B
FY202431 Dec 20247.09%5.50B77.51B
FY202331 Dec 20236.84%5.06B74.04B
FY202231 Dec 202210.66%7.97B74.78B
FY202131 Dec 20219.06%6.22B68.68B
FY202031 Dec 202019.51%12.31B63.11B
FY201931 Dec 20193.15%1.86B58.93B
FY201831 Dec 20187.31%4.31B58.88B
FY201731 Dec 201714.52%8.43B58.07B
FY201631 Dec 20168.18%4.71B57.55B
FY201531 Dec 20157.39%4.29B58.05B
FY201431 Dec 20147.82%4.39B56.12B
FY201331 Dec 20136.53%3.72B56.90B
FY201231 Dec 20128.66%4.97B57.33B
FY201131 Dec 201110.13%5.69B56.20B
FY201031 Dec 201010.30%5.47B53.10B
FY200931 Dec 200910.93%5.27B48.19B
FY200831 Dec 20088.58%3.85B44.87B
FY200731 Dec 200711.84%5.27B44.54B
FY200631 Dec 20068.78%4.01B45.60B
FY200531 Dec 20054.89%2.26B46.13B
FY200431 Dec 2004-8.79%-3.61B41.06B
FY200331 Dec 200332.83%2.07B6.31B
FY200231 Dec 200229.14%1.76B6.04B
FY200131 Dec 200127.48%1.59B5.77B
FY200031 Dec 200022.89%985.00M4.30B
FY199931 Dec 199917.47%625.00M3.58B

Figures in EUR. A quarter's revenue, net income and dividends are those of its last four quarters.

See also:P/E ratio,Market cap,P/S ratio,Debt to equity,Current ratio,All ratios

Common questions about Sanofi ADS's ROE

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.